Board Member
Manoj Monga, MD FACS
Co-inventor of Oxalytic TM and a nationally recognized urologist whose clinical and research leadership is centered on endourology, kidney stone disease, and urologic device innovation.
Bio
Manoj Monga, MD, FACS, is a board member of NanoXomics and co-inventor of Oxalytic TM. He is an internationally recognized urologist whose work integrates kidney stone disease, endourology, clinical innovation, and translational device research.
Dr. Monga has extensive expertise in kidney stone prevention, medical and surgical management, and minimally invasive treatment. His research has also advanced the evaluation and design of technologies for endourologic care, providing a strong clinical framework for translating scientific discoveries into practical interventions.
At NanoXomics, Dr. Monga provides clinical and translational leadership for Oxalytic TM, helping align its microbiome-based therapeutic and biomarker strategy with the needs of patients with kidney stone disease and broader opportunities at the intersection of microbial function, patient stratification, and urologic outcomes.